Synapse - Shanu Modi

Search Within

Shanu Modi

Results (113)

A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer

Journal Article

Fornier, M. N.; Morris, P. G.; Abbruzzi, A.; D'Andrea, G.; Gilewski, T.; Bromberg, J.; Dang, C.; Dickler, M.; Modi, S.; Seidman, A. D.; more...
Annals of Oncology (2011)

Fulltext@MSK | Save

HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab

Journal Article

Modi, S.; Stopeck, A.; Linden, H.; Solit, D.; Chandarlapaty, S.; Rosen, N.; D'Andrea, G.; Dickler, M.; Moynahan, M. E.; Sugarman, S.; more...
Clinical Cancer Research (2011)

Fulltext@MSK | Save

A feasibility study of bevacizumab plus dose-dense doxorubicin- cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer

Journal Article

Mcarthur, H. L.; Rugo, H.; Nulsen, B.; Hawks, L.; Grothusen, J.; Melisko, M.; Moasser, M.; Paulson, M.; Traina, T.; Patil, S.; more...
Clinical Cancer Research (2011)

Fulltext@MSK | Save

Correlative biomarkers in a phase II study of dasatinib (D) and weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)

Meeting Abstract

Morris, P. G.; Chang, J. C.; Abbruzzi, A.; Patil, S.; Modi, S.; Seidman, A. D.; Sklarin, N. T.; Norton, L.; Hudis, C.; Fornier, M. N.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Pharmacokinetics (PK) of trastuzumab-DM1 (T-DM1) and paclitaxel (T) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen

Meeting Abstract

Lu, D.; Krop, I.; Modi, S.; Elias, A.; LoRusso, P.; Huang, J.; Lu, M.; Girish, S.
Cancer Research (2010)

Fulltext@MSK | Save

A phase I-II trial of dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)

Meeting Abstract

Morris, P. G.; Abbruzzi, A.; D'Andrea, G.; Gilewski, T.; Lake, D.; Bromberg, J.; Dang, C.; Dickler, M.; Modi, S.; Seidman, A. D.; more...
Cancer Research (2010)

Fulltext@MSK | Save

Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results

Journal Article

Morris, P. G.; Van Poznak, C.; Modi, S.; Mak, A. F.; Patil, S.; Larson, S.; Hudis, C. A.; Divgi, C.; Grewal, R. K.
Clinical Breast Cancer (2010)

Fulltext@MSK | Save

Safety of a novel capecitabine dosing schedule when combined with lapatinib in patients with HER2-positive metastatic breast cancer refractory to trastuzumab

Meeting Abstract

Traina, T. A.; Theodoulou, M.; Feigin, K.; Patil, S.; Geneus, S.; Modi, S.; Fornier, M.; Lake, D.; Norton, L.; Hudis, C.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results

Meeting Abstract

Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; more...
Cancer Research (2009)

Fulltext@MSK | Save

Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)

Meeting Abstract

Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Kersey, K.; Johnson, R. G.; Rosen, N.; Hannah, A. L.; Hudis, C. A.
Journal of Clinical Oncology (2008)

Fulltext@MSK | Save